Aravax is a Melbourne-based biotechnology startup focused on developing a safe and effective treatment for peanut allergy. The company was born out of years of research at the Australian National University and CSIRO, Australia's national science agency. Aravax's core product, PVX108, utilizes peptide immunotherapy to desensitize individuals to peanut allergens, aiming to provide a long-term solution for those suffering from peanut allergies.

Aravax leverages the expertise of its team, which includes renowned scientists and experienced industry professionals, to advance its research and development efforts. The company is committed to improving the quality of life for individuals with peanut allergies and looks forward to conducting further clinical trials to validate the efficacy of PVX108.

Connect